Elexacaftor / ivacaftor / tezacaftor
RxNorm 2257010
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2257010 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: elexacaftor / ivacaftor / tezacaftor.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
MINPrescribable
Multiple Ingredients (MIN):
Elexacaftor / ivacaftor / tezacaftor
(Atom ID: 11796108)
PTPrescribable
Designated preferred name (PT):
Elexacaftor- and ivacaftor- and tezacaftor-containing product
(Atom ID: 11824874)
FNPrescribable
Full form of descriptor (FN):
Product containing elexacaftor and ivacaftor and tezacaftor (medicinal product)
(Atom ID: 11826281)
Patient Education
Elexacaftor, Tezacaftor, and Ivacaftor
The combination of elexacaftor, tezacaftor, and ivacaftor is used to treat certain types of cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction) in adults and children 12 years of age and older. It should be used only in people with a certain genetic make-up. Your doctor may order a blood test to help decide if this medication is right for you. Elexacaftor and tezacaftor are in a class of medications called cystic fibrosis transmembrane conductance regulator (CFTR) correctors. Ivacaftor is in a class of medications called cystic fibrosis transmembrane conductance regulator (CFTR) potentiators. These medications work by improving the function of a protein in the body to decrease the build-up of thick mucus in the lungs and improve other cystic fibrosis symptoms.
[Learn More]
* Please review the disclaimer below.